Study Finds Treatment With Metreleptin Improved Diabetes And Lipid Control In Patients With Partial Lipodystrophy

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a study that showed treatment with metreleptin, an investigational treatment that is an analog of the human hormone leptin, improved diabetes and lipid control in patients with partial lipodystrophy. Data from this study, the first findings from patients receiving metreleptin through Amylin's lipodystrophy expanded access program, were presented at the 93rd Annual Meeting and Expo of The Endocrine Society (ENDO) in Boston. In this study, being conducted under a treatment IND authorized by the U.S...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/2jl1vf1W4i8/227574.php

nutrition weight loss